Cytokinetics to Announce Second Quarter Results on August 8, 2024
July 25, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at...
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
July 16, 2024 07:30 ET
|
Cytokinetics, Incorporated
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 03, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
June 17, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics to Participate in June Investor Conferences
May 29, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Announces Closing of Public Offering of Common Stock
May 28, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of...
Cytokinetics Announces Pricing of Public Offering of Common Stock
May 22, 2024 23:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its...
Cytokinetics Announces Proposed Public Offering of Common Stock
May 22, 2024 16:02 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500...
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a...